Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

TB treatment news

Show

From To
TAG Pipeline Report

2015 report on the pipeline for new HIV, HCV and TB drugs.

Published
17 July 2015
From
TAG
High-dose rifampicin may shorten time to TB clearance

A combination regimen containing high-dose rifampicin (also known as rifampin) was associated with faster tuberculosis (TB) bacteria culture conversion in people with drug-sensitive TB, but moxifloxacin and

Published
13 April 2015
By
Liz Highleyman
Ukraine: Concurrent treatment for HIV/TB co-infection breaks up “deadly alliance”

USAID funded MEASURE Evaluation to initiate an impact evaluation in Ukraine for two TB programmatic priorities: Improving integration of TB and HIV services to reduce mortality through early diagnosis and treatment for co-infected patients; and providing social support services to improve TB treatment adherence.

Published
30 March 2015
From
Science Speaks
Final fight pays off, XXDR-TB & HIV patient cured

Once an active case of extremely drug resistant (XXDR-TB) strain of tuberculosis or totally drug resistant (TDR) TB, 40-year-old Rashid Khan (name changed), has now been completely cured of his disease. Despite having total drug resistance and HIV infection, Khan got cured a few days ago. At one stage he was receiving a cocktail of 18–20 drugs between his HIV and TB regimes. But Bedaquiline made a huge difference in his treatment. He is off medicine now.

Published
24 March 2015
From
DNAIndia
Lancet: Phase 2b trial results of novel TB regimen show potential to shorten treatment

A new tuberculosis (TB) drug regimen designed to improve options for TB therapy eliminated more bacteria from sputum than standard therapy, worked for people with multi-drug-resistant (MDR) TB, and did so in a quarter of the time, according to data from a phase 2b clinical trial published today in The Lancet. These results are published just as the global phase 3 clinical trial, STAND, designed to bring this regimen through the last stage of testing, has begun. The PaMZ regimen uses pretomanid, a new drug; moxifloxacin, an established antibiotic that is experimental as a TB treatment; and pyrazinamide, an established TB drug. Twenty percent of the TB patients enrolled in NC-002 also were co-infected with HIV and the PaMZ regimen appeared to be effective independent of HIV status. See also http://www.aidsmap.com/Novel-TB-regimen-could-reduce-treatment-duration/page/2892700/

Published
18 March 2015
From
Lancet (free registration required)
TB drug candidate starts Phase 1 trial — first in six years

The enrollment of nearly 50 volunteers in the United States will launch the first randomized clinical trial of a potential  new drug to treat TB in six years, the nonprofit product development partnership TB Alliance announced Wednesday.

Published
20 February 2015
From
Science Speaks
ART during tuberculosis therapy reduces mortality risk for people with HIV

There is a high mortality rate among people living with HIV undergoing treatment for tuberculosis (TB), according to the results of a meta-analysis published in PLOS One.

Published
19 December 2014
By
Michael Carter
TB Alliance Launches Phase 2B Clinical Trial of a Novel TB Drug Regimen that Could Cut Treatment Time by Half or More for a Majority of TB Patients

NC-005 trial tests a novel regimen of bedaquiline (Sirturo), pretomanid (formerly known as PA-824), and pyrazinamide; results could pave the way for a three-month TB treatment.

Published
27 October 2014
From
TB Alliance
Bedaquiline as part of tailored therapy for MDR- and XDR-TB achieves impressive culture conversion rates

Use of the new anti-tuberculosis (TB) drug bedaquiline as part of a tailored regimen achieved high rates of culture conversion in people with multidrug-resistant TB (MDR-TB) and extensively

Published
27 October 2014
By
Michael Carter
Newly identified marker helps predict tuberculosis complications in HIV patients

An NIAID study suggests that the increased frequency of an immune cell called CD14++CD16- monocyte is a strong indicator that a patient with HIV and tuberculosis (TB) may develop immune reconstitution inflammatory syndrome (IRIS).

Published
16 October 2014
From
National Institute of Allergy and Infectious Diseases (NIAID) press release
← First12345...14Next →

Filter by country